Focus & Expertise
Since day one, we have maintained a singular focus on iPSCs. Every investment we make and every experience we build directly strengthens our core, delivering greater value to you.
Full-spectrum manufacturing services and pre-established platforms enabling drug developers to deliver scalable immune-oncology and regenerative medicine cell therapies faster and with commercially viable cost structures

As the global leader in allogeneic iPSC-derived cell therapy manufacturing, we offer established cell line development, process development, GMP manufacturing platforms, ready-to-use iPSC lines, and proprietary gene-editing capabilities.
Which means Cellistic is ready right now to help you identify and accelerate your highest-value opportunities — especially if you’re looking to serve a much larger market than is possible with an autologous or donor-derived allogeneic approach.


See how Cellistic can remove the scientific, operational, and economic barriers to scalable patient delivery. And, over time, help ensure the use of extraordinary therapies becomes a very ordinary thing.

Cellistic integrates the services, platforms, and expertise required to enable successful iPSC-derived allogeneic cell therapy GMP manufacturing – and we’re continually expanding our capabilities with a single purpose in mind: to help you limit risk, accelerate time to clinic, and reduce costs.
Platforms + Technologies
Pulse™ Platform for iPSC cell line development and Cellistic Echo Platform for scalable GMP manufacturing that put your program on a faster track
CDMO Services
Full-spectrum services tuned to your program’s distinct needs and deployed to streamline its progress
Cell Types
Broad, deep expertise in (iPSC-derived) cell types that removes the uncertainties of harnessing their full potential
Other cell therapy manufacturers may offer iPSC platforms or development services, but only Cellistic provides a truly integrated solution, built on a singular iPSC focus, ensuring programs transition seamlessly from discovery to GMP without reinventing the process.
Since day one, we have maintained a singular focus on iPSCs. Every investment we make and every experience we build directly strengthens our core, delivering greater value to you.
With flexible, pre-built platforms featuring integrated modules that enable end-to-end workflows, we empower your program to advance efficiently, cost-effectively and with less risk.
iPSCs are unique. We understand exactly what it takes to move from concept through research, development, and manufacturing, fully leveraging their a
iPSCs are unique. We understand exactly what it takes to move from concept through research, development, and manufacturing, fully leveraging their advantages without tech transfer risk. Our business models are flexible enough to work with any size company.
dvantages without tech transfer risk. Our business models are flexible enough to work with any size company.
Whether you’re pursuing an autologous cell therapy or already have an iPSC-based project underway, Cellistic offers a practical and proven path forward for your cell therapy or regenerative medicine — making it possible to turn a high-potential idea into a viable therapeutic faster and more efficiently.

| iPSC-Derived Allogeneic | Autologous | Donor-Derived Allogeneic | |
|---|---|---|---|
| Your opportunity |
Transfer an existing process to a flexible, full-scale, iPSC-focused CDMO |
Go from one-to-one to one-to-many using our proven platforms |
Overcome limitations to increase scale, consistency, quality, and characterization |
Our headquarters in Mont-Saint-Guibert, Belgium, is home to the first EMA-certified and FDA and PMDA compliant purpose-built iPSC cell therapy GMP manufacturing facility.
With all capabilities in a single location, our clients collaborate closely with our multidisciplinary team, with everyone aligned on the shared goal: developing and manufacturing iPSC-based allogeneic cell therapies as efficiently and cost-effectively as possible.

Let’s start with what’s on your mind – your project plans, your questions about iPSC technology, your most pressing scientific and business drivers. We’re here to listen and, if we’re a good fit, to help you maximize the opportunity and value of your cell therapy.